Article

The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma

2025-04-19

Abstract excerpt

DIRECT was a prospective, multisite study assessing the feasibility and utility of circulating tumor DNA (ctDNA) in 188 patients with aggressive B-cell non-Hodgkin lymphoma using a lymphoma-customized assay and open-source pipeline. CtDNA fraction assessed by copy number alterations in pre-treatment plasma identified high-risk patients more effectively than existing clinical risk scores. In 74.5% of cases ctDNA wa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1ae644de-6b2a-57da-9817-a940f1d68c77
DOI: 10.1101/2025.04.14.25325806

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell LymphomaDOI 10.1101/2025.04.14.25325806Read

Circulating Tumor DNA in Lymphoma.Semantic proximity Read

Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell MalignanciesSemantic proximity Read

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read

Circulating Tumor DNA in Lymphoma: Principles and Future DirectionsSemantic proximity Read

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational researchSemantic proximity Read

NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL.Semantic proximity Read

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Semantic proximity Read

Circulating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime?Semantic proximity Read

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Semantic proximity Read

Clinical use of circulating tumor DNA analysis in patients with lymphomaSemantic proximity Read

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.Semantic proximity Read

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity Read